Compare Advance Auto Parts, Inc. (AAP) vs AbbVie Inc (ABBV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs AbbVie Inc — how do they compare? Advance Auto Parts, Inc. trades at $53.1 (market cap $3.36B), while AbbVie Inc trades at $250.09 (market cap $438.19B). The key difference: AbbVie Inc is far larger — about 130.4× Advance Auto Parts, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| AAP | ABBV | |
|---|---|---|
Market Cap | $3.36B | $438.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $263.58 |
52-Week Low | $38.75 | $197.38 |
Enterprise Value | $5.63B | $502.45B |
Dividend Yield | 1.79% | 2.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $57.80, down 0.21% on the day, with a bullish technical signal and key support at $57. The company shows mixed fundamentals: a low P/S of 0.41 and strong recent earnings beats, but thin net margins of 0.51% and negative operating cash flow in 2025. News highlights restructuring efforts and AI-driven delivery initiatives as potential growth catalysts.
The outlook is cautiously optimistic; analyst consensus targets $61.30 with a buy rating, but high debt and competitive pressures pose risks. Earnings momentum and valuation appeal offer upside, yet execution on turnaround plans is critical for sustained recovery.
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →
